Arctic Bioscience AS informs that Jone Slinning has decided to step down from the position as Chief Financial Officer (CFO) to pursue opportunities outside the Company. Jone Slinning will continue in the role until 31.12.2026 and will assist in securing an orderly transition of responsibilities. The Board of Directors would like to thank Jone for his contribution during the tenure with the Company and wishes him every success in future endeavors.
The Company has initiated a process to appoint a successor and will provide further updates in due course.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
For more information, please contact:
Christer L. Valderhaug
CEO
Mobile: +47 920 84 601
E-mail: christer@arctic-bioscience.com
About Arctic Bioscience
Arctic Bioscience is a biotech company developing and commercializing pharmaceutical and nutraceutical products based on unique bioactive marine compounds.
The company is developing HRO350 – a novel oral drug candidate. HRO350 is being developed for treatment of patients with mild-to-moderate psoriasis. This is a large patient group in need of new effective medicines with beneficial safety profile.
Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as well as finished goods under the ROMEGA® brand.
Arctic Bioscience is led by a highly skilled team of talents with diverse and highly relevant background.